Novavax announced Thursday its vaccine candidate proved to be 96.4% effective against mild, moderate and severe cases of COVID-19 in a Phase 3 trial in the United Kingdom.
Pfizer vaccine shows 100 percent efficacy in people ages 12-15
WXXVDT2
Pfizer’s COVID-19 vaccine is effective in adolescents.
